Efficacy
The objective response rate for all patients was 34% (35% for first-line and 32% for second-line patients).
The median duration of objective response was 34 weeks in both groups and the overall survival in first- and second- line patients were 67 weeks and 62 weeks respectively.
Summary of efficacy r

© Journal of Clinical Oncology 1995
Kaplan-Meier estimates of time to disease progression r

© Journal of Clinical Oncology 1995
Kaplan-Meier estimates of survival r

© J Clin Oncol 1995